Resources | NITAG RESOURCE CENTER

2024 ∙ NACI

Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines

2024 ∙ NACI

Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines

2024 ∙ JCVI

JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future COVID-19 vaccination

2024

Considerations to inform country COVID-19 vaccination decision-making

2024 ∙ NACI

Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19

2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.

A review of factors influencing vaccination policies and programs for older adults globally

2023 ∙ Vraga, Emily K. Brady, Sonya S. Gansen, Chloe Khan, Euna Mehnaz Bennis, Sarah L. Nones, Madalyn Tang, Rongwei Srivastava, Jaideep Kulasingam, Shalini

A review of HPV and HBV vaccine hesitancy, intention, and uptake in the era of social media and COVID-19

2023 ∙ Xu, K. Wang, Z. Qin, M. Gao, Y. Luo, N. Xie, W. Zou, Y. Wang, J. Ma, X.

A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults

2023 ∙ Chen, S. Wei, W. Huang, F. Wang, J. Li, X. Gen, Z. Gao, F. Dong, T. Wei, P. Yang, X. Miao, F.

A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients

2023 ∙ Mohammed, H. Pham-Tran, D. D. Yeoh, Z. Y. M. Wang, B. McMillan, M. Andraweera, P. H. Marshall, H. S.

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)